{"id":"standard-dose-oral-anticoagulant","safety":{"commonSideEffects":[{"rate":"1-4% per year for major bleeding","effect":"Bleeding (major and minor)"},{"rate":"<1%","effect":"Warfarin-induced skin necrosis"},{"rate":"1-2%","effect":"Gastrointestinal bleeding"},{"rate":"0.5-1%","effect":"Intracranial hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oral anticoagulants work by blocking the synthesis of vitamin K-dependent coagulation factors (II, VII, IX, and X) in the liver, thereby reducing the ability of blood to clot. This prevents the formation and extension of blood clots in conditions where thromboembolism is a risk. They are used for long-term anticoagulation in conditions such as atrial fibrillation, venous thromboembolism, and mechanical heart valves.","oneSentence":"Standard dose oral anticoagulants inhibit vitamin K-dependent clotting factors to prevent thrombus formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:09:13.391Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention"},{"name":"Mechanical heart valve thromboprophylaxis"}]},"trialDetails":[{"nctId":"NCT07479147","phase":"","title":"SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2025-12-16","conditions":"Ischemic Stroke, Embolic Stroke of Undetermined Source, Patent Foramen Ovale (PFO)","enrollment":400},{"nctId":"NCT07456085","phase":"PHASE3","title":"Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves","status":"ENROLLING_BY_INVITATION","sponsor":"Rawalpindi Institute of Cardiology","startDate":"2025-11-13","conditions":"Valvular Heart Disease Patients","enrollment":60},{"nctId":"NCT07454707","phase":"PHASE3","title":"Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-04","conditions":"Stroke, Ischemic","enrollment":1204},{"nctId":"NCT06037889","phase":"PHASE3","title":"Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2023-11-09","conditions":"Branch Atheromatous Disease","enrollment":516},{"nctId":"NCT07432529","phase":"PHASE3","title":"Design and Rationale of the COLT Study","status":"NOT_YET_RECRUITING","sponsor":"Azienda Sanitaria Locale ASL 6, Livorno","startDate":"2026-06-01","conditions":"Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome, Venous Thromboembolism (VTE)","enrollment":940},{"nctId":"NCT06094920","phase":"PHASE4","title":"Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2024-07-29","conditions":"Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":12},{"nctId":"NCT07005024","phase":"PHASE3","title":"DOAC - Dosing Options in AntiCoagulation Prophylaxis","status":"RECRUITING","sponsor":"University of Vermont","startDate":"2025-10-17","conditions":"Cancer, VTE (Venous Thromboembolism)","enrollment":996},{"nctId":"NCT07290608","phase":"NA","title":"DOACT Algorithm Versus AI-Based Decision Models in Oral Anticoagulant Therapy for Vascular Patients","status":"COMPLETED","sponsor":"ITALO EUGENIO SOUZA GADELHA DE ABREU","startDate":"2025-01-20","conditions":"Deep Vein Thrombosis, Superficial Thrombophlebitis, Pulmonary Thromboembolisms","enrollment":59},{"nctId":"NCT06195540","phase":"PHASE3","title":"RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2024-07-19","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":1424},{"nctId":"NCT07228663","phase":"PHASE3","title":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-12-01","conditions":"Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE)","enrollment":100},{"nctId":"NCT02969746","phase":"PHASE4","title":"Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants","status":"WITHDRAWN","sponsor":"University Hospital, Angers","startDate":"2014-07-18","conditions":"Anticoagulants; Circulating, Hemorrhagic Disorder","enrollment":""},{"nctId":"NCT07208695","phase":"","title":"Effect of Oral Antiplatelet or Anticoagulant Drugs on Postoperative Bleeding Risk and Venous Closure Rate in Patients With Lower Extremity Varicose Veins After Radiofrequency Ablation","status":"NOT_YET_RECRUITING","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2025-10-01","conditions":"Oral Antiplatele, Anticoagulant Drugs, Lower Extremity Varicose Veins","enrollment":40},{"nctId":"NCT05990894","phase":"","title":"Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-07-01","conditions":"Cerebral Venous Thrombosis","enrollment":170},{"nctId":"NCT05643651","phase":"PHASE4","title":"Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-06-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm","enrollment":100},{"nctId":"NCT03630055","phase":"PHASE3","title":"Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2018-10-03","conditions":"Radial Artery Occlusion","enrollment":1800},{"nctId":"NCT04979884","phase":"PHASE3","title":"Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-01-03","conditions":"COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Pulmonary Fibrosis","enrollment":66},{"nctId":"NCT05735639","phase":"PHASE4","title":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-01-22","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":6660},{"nctId":"NCT05627375","phase":"PHASE3","title":"Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2023-08-16","conditions":"Venous Thromboembolic Disease","enrollment":1400},{"nctId":"NCT02798471","phase":"PHASE3","title":"Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-03-27","conditions":"Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)","enrollment":290},{"nctId":"NCT06749834","phase":"PHASE3","title":"Intravenous Thrombolysis and NOAC","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-01-27","conditions":"Acute Ischemic Stroke","enrollment":280},{"nctId":"NCT04437654","phase":"PHASE4","title":"The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2020-07-28","conditions":"Atrial Fibrillation Patients With Intermediate Stroke Risk","enrollment":1800},{"nctId":"NCT06352632","phase":"PHASE3","title":"ACT-GLOBAL Adaptive Platform Trial for Stroke","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-26","conditions":"Stroke","enrollment":20000},{"nctId":"NCT06615596","phase":"EARLY_PHASE1","title":"Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-01","conditions":"Atrial Fibrillation (AF)","enrollment":3160},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT06487052","phase":"NA","title":"Evaluation of the Standard Catheter-directed Thrombolysis Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients","status":"RECRUITING","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2024-01-10","conditions":"Pulmonary Embolism Acute","enrollment":100},{"nctId":"NCT05472766","phase":"NA","title":"Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-11-24","conditions":"Subdural Hematoma, Atrial Fibrillation","enrollment":1},{"nctId":"NCT03759938","phase":"NA","title":"OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2019-06-18","conditions":"Stroke, Acute, Atrial Fibrillation","enrollment":3648},{"nctId":"NCT06196398","phase":"","title":"Effects of Medical Treatment of ICAS With Hemodynamic Disorders Based on MR-FFR","status":"UNKNOWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-01-01","conditions":"Stroke, Ischemic, Intracranial Atherosclerosis","enrollment":400},{"nctId":"NCT04436978","phase":"PHASE4","title":"What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?","status":"RECRUITING","sponsor":"St. Antonius Hospital","startDate":"2023-01-11","conditions":"Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation","enrollment":2000},{"nctId":"NCT04569279","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin in CVT Treatment","status":"COMPLETED","sponsor":"Damascus University","startDate":"2017-09-01","conditions":"Cerebral Vein Thrombosis","enrollment":71},{"nctId":"NCT02666742","phase":"PHASE4","title":"DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation","status":"COMPLETED","sponsor":"Kansas City Heart Rhythm Institute","startDate":"2017-02-16","conditions":"Ventricular Tachycardia, Premature Ventricular Contraction, Stroke","enrollment":246},{"nctId":"NCT01999179","phase":"NA","title":"Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2014-06","conditions":"Venous Thrombosis, Neoplasms","enrollment":27},{"nctId":"NCT04727437","phase":"PHASE3","title":"STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism","status":"UNKNOWN","sponsor":"University of Birmingham","startDate":"2021-04-08","conditions":"Subsegmental Pulmonary Embolism Nos","enrollment":1466},{"nctId":"NCT04981327","phase":"PHASE3","title":"The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Geneva","startDate":"2022-09-01","conditions":"Deep Vein Thrombosis","enrollment":1300},{"nctId":"NCT04788355","phase":"PHASE3","title":"Prevention of Complications (SARS-CoV-2): Clinical Study","status":"COMPLETED","sponsor":"Universidade do Vale do Sapucai","startDate":"2020-07-01","conditions":"Complication","enrollment":176},{"nctId":"NCT04412291","phase":"PHASE2","title":"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2020-06-11","conditions":"Covid-19","enrollment":120},{"nctId":"NCT03073850","phase":"PHASE4","title":"Antithrombotic Treatment in Patients With Effectively Maintained Sinus Rhythm After Atrial Fibrillation Ablation","status":"TERMINATED","sponsor":"Korea University Guro Hospital","startDate":"2017-02-23","conditions":"Atrial Fibrillation","enrollment":48},{"nctId":"NCT02984982","phase":"PHASE4","title":"Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-15","conditions":"Hypercholesterolemia, Acute Coronary Syndrome","enrollment":206},{"nctId":"NCT03818451","phase":"NA","title":"Co-ultra PEALut Enhances Neuronal Recovery Following Moderate Traumatic Brain Injury","status":"UNKNOWN","sponsor":"University of Messina","startDate":"2016-05-01","conditions":"Traumatic Brain Injury","enrollment":60},{"nctId":"NCT00790335","phase":"PHASE3","title":"Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-11","conditions":"Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome","enrollment":692},{"nctId":"NCT01083732","phase":"PHASE2","title":"Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-03","conditions":"Venous Thromboembolism","enrollment":18},{"nctId":"NCT02223260","phase":"PHASE2","title":"Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-09","conditions":"Venous Thromboembolism","enrollment":8},{"nctId":"NCT01773174","phase":"PHASE2","title":"Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2013-01","conditions":"Venous Thromboembolism","enrollment":""},{"nctId":"NCT00994292","phase":"PHASE2","title":"Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2009-09","conditions":"Acute Coronary Syndrome","enrollment":1276},{"nctId":"NCT01850277","phase":"PHASE4","title":"Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2013-10","conditions":"Atrial Fibrillation, Heart Failure","enrollment":60},{"nctId":"NCT01954238","phase":"PHASE1","title":"A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2013-08","conditions":"Healthy Volunteers","enrollment":46},{"nctId":"NCT00119457","phase":"PHASE2","title":"Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)","status":"COMPLETED","sponsor":"vTv Therapeutics","startDate":"2005-01","conditions":"Venous Thromboembolism, Embolism and Thrombosis, Hip Fractures","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Edoxaban of 60mg"],"phase":"marketed","status":"active","brandName":"Standard dose oral anticoagulant","genericName":"Standard dose oral anticoagulant","companyName":"Korea University Guro Hospital","companyId":"korea-university-guro-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Standard dose oral anticoagulants inhibit vitamin K-dependent clotting factors to prevent thrombus formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Mechanical heart valve thromboprophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}